Norman W. Wong
Suite 300, 4820 Richard Road SW
Calgary, AB T3E6L1, Canada
Calgary, AB T3E6L1, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation.
Journal: Translational neuroscience
Published: September 25, 2023
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
Journal: International immunopharmacology
Published: December 14, 2022
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells.
Journal: Atherosclerosis
Published: April 25, 2022
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Journal: American journal of preventive cardiology
Published: April 18, 2022
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 01, 2022
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.
Journal: Pharmacology research & perspectives
Published: December 25, 2021
Insulin mimetic effect of D-allulose on apolipoprotein A-I gene.
Journal: Journal of food biochemistry
Published: September 20, 2021
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.
Journal: Journal of Alzheimer's disease : JAD
Published: August 30, 2021
Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.
Journal: Biomedicines
Published: March 22, 2021
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Journal: Cardiovascular diabetology
Published: March 06, 2021
Last Updated: 09/26/2026